



Siemens Medical Solutions USA Inc.
Martin Rajchel
Regulatory Affairs Specialist
40 Liberty Boulevard, Mail Code 65-IA
Malvern, Pennsylvania 19355

October 26, 2018

Re: K182299

Trade/Device Name: MAGNETOM Aera
Regulation Number: 21 CFR 892.1000
Regulation Name: Magnetic Resonance Diagnostic Device
Regulatory Class: Class II
Product Code: LNH
Dated: August 23, 2018
Received: August 24, 2018

Dear Martin Rajchel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Michael D. O'hara -S
Digitally signed by Michael D. O'hara -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300226759, cn=Michael D. O'hara -S
Date: 2018.10.26 08:34:51 -04'00' For

Robert A. Ochs, Ph.D.
Director
Division of Radiological Health
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

k182299

Device Name

MAGNETOM Aera

Indications for Use (Describe)

Your MAGNETOM system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.

Your MAGNETOM system may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR § 807.92.

Company: Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard, 65-1A
Malvern, PA 19355

Date Prepared: August 23, 2018

1. General Information

Importer/Distributor:

Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard, Mail Code 65-1A
Malvern, PA 19355, USA
Establishment Registration Number: 2240869

Manufacturing Sites:

Siemens Healthcare GmbH
Henkestrasse 127
91052 Erlangen, Germany
Establishment Registration Number: 3002808157

SIEMENS SHENZHEN MAGNETIC RESONANCE LTD.
Siemens MRI Center
Hi-Tech Industrial park (middle)
Gaoxin C. Ave., 2nd
Shenzhen 518057, P.R. CHINA
Establishment Registration Number: 3004754211

2. Contact Person:

Martin Rajchel
Regulatory Affairs Specialist
Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard, 65-1A
Malvern, PA 19355, USA
Phone: (610) 448-6545
Fax: (610) 640-4481
E-mail: martin.rajchel@siemens-healthineers.com

3. Device Name and Classification:

Device Name	MAGNETOM Aera with <i>syngo</i> MR E11C-AP01 software
Trade Name	MAGNETOM Aera
Classification Name	Magnetic Resonance Diagnostic Device (MRDD)
Classification Panel:	Radiology
Regulation Number:	21 CFR § 892.1000
Device Class:	II
Primary Product Code:	LNH
Secondary Product Code:	LNI, MOS

4. Legally Marketed Predicate Device:

Device Name	MAGNETOM Aera, MAGNETOM Skyra / Skyra ^{fit} , MAGNETOM Prisma / Prisma ^{fit} and MAGNETOM Avanto ^{fit} with <i>syngo</i> MR E11C - AP04 software
Trade Names:	MAGNETOM Aera, MAGNETOM Skyra / Skyra ^{fit} , MAGNETOM Prisma / Prisma ^{fit} and MAGNETOM
510(k) Number:	K173592, cleared February 13, 2018
Classification Name	Magnetic Resonance Diagnostic Device (MRDD)
Classification Panel:	Radiology
Regulation Number:	21 CFR § 892.1000
Device Class:	II
Primary Product Code:	LNH
Secondary Product Code:	LNI, MOS

5. Intended Use

The indications for use for the subject device are the same as the predicate device:

Your MAGNETOM system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.

Your MAGNETOM system may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.

6. Device Description:

The application package AP01, “Implant Suite” for MAGNETOM Aera, enables diagnostic imaging for patients with MR Conditional active and passive implants. Three different Fixed Parameter Options (FPO), Scan Limits 1, 2, and 3, provide conditional implant scan limitations as shown below:

Fixed Parameter Options	B1+ peak	B1+ rms	WB SAR	dB/dt peak	dB/dt rms	Slew rate
Scan Limits 1	-	-	≤ 2 W/kg	-	-	≤ 200 T/m/s
Scan Limits 2	-	≤ 2.0 μ T	≤ 0.8 W/kg	-	-	≤ 200 T/m/s
Scan Limits 3	≤ 30 μ T	≤ 2.0 μ T	≤ 0.8 W/kg	≤ 50 T/s	≤ 56 T/s	≤ 125 T/m/s

Without a scan limitation selected, the subject device operates identically to the predicate device. The AP01 application package, “Implant Suite”, is an optional feature.

With application package AP01, “Implant Suite” for MAGNETOM Aera, the following changes are introduced:

Hardware Modified Hardware

- Additional segregated control path to safely switch-off the gradient power in case the limits are reached during a scan
- Additional supply-voltage supervisions in the gradient amplifier
- Additional measures to ensure permanent active RF sensor data communication
- Additional segregated TX- switch-off path (TSO box)
- New computer hardware for MRAWP and MRWP due to obsolescence

Software New Features and Applications

- Implant Suite (*syngo* MR E11C-AP01) Including:
 - New Online Patient Safety supervision (OPS) interface
 - New safe reaction (switch-off) path for when implant related limits are exceeded
 - Extended look-ahead functionality (prediction) to avoid starting sequences that could potentially exceed implant-related limits
 - New internal supervision to detect latent failures in the control path
 - New Implant Suite UI (IUI)
 - New means to control coil usage
 - Adapted pulse sequences with restricted operation mode

7. Technological Characteristics

The subject device, MAGNETOM Aera with *syngo* MR E11C-AP01, has the same fundamental technological characteristics as the predicate device, MAGNETOM Aera with *syngo* MR E11C-AP04, (K173592 cleared February 13, 2018) with regard to the operational environment, programming language, operating system, and performance.

The software was modified to implement a new user interface and limitations for scanning patients with MR Conditional implants. Additionally the hardware was modified to implement safe communication channels and a safe cut-off path for RF power.

The MAGNETOM Aera with *syngo* MR E11C-AP01 conforms to the standard for software medical devices (IEC 62304:2015) and other relevant IEC and NEMA standards.

While there are some differences in technological characteristics between the subject device and predicate device, including new and modified software applications and hardware additions, these differences have been tested and the conclusions from the non-clinical data suggests that the features bear an equivalent safety and performance profile to that of the predicate device.

8. Nonclinical Tests

The following performance testing was conducted on the subject device:

- Image quality assessments of the modified measurement protocols
- Verification testing of the new Fixed Parameter Options (FPO) and respective limitations
- Software verification and validation testing was completed in accordance with the FDA guidance document, *"Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices"* (May 11, 2005)

The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate device to which it has been compared.

9. Clinical Tests

No clinical tests were conducted to support substantial equivalence for the subject device; however, clinical images were provided to support the imaging performance of the device when using the limitations of the new "Implant Suite" feature.

10. Safety and Effectiveness

The device labeling contains instructions for use and any necessary cautions and warnings to ensure safe and effective use of the device.

Risk management is ensured via ISO 14971:2007 compliance to identify and provide mitigation to potential hazards in a risk analysis beginning early in the design phase and continuing throughout the development of the product. These risks are controlled via measures realized in hardware and software development, testing, and product labeling. To minimize risks, Siemens adheres to recognized and established industry practices and standards, such as the IEC 60601-1 series, to minimize electrical and mechanical risk. Software development is carried out according to the IEC 62304 standard for medical device software. Furthermore, the device is intended for healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.

The MAGNETOM Aera with *syngo* MR E11C-AP01 software conforms to the applicable FDA recognized and international IEC, ISO and NEMA.

Recognition Number	Product Area	Title of Standard	Reference Number and date	Standards Development Organization
19-4	General	C1:2009/(R)2012 and A2:2010/(R)2012 (Consolidated Text) Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD)	ES60601-1:2005/(R)2012 and A1:2012	AAMI ANSI
19-8	General	Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests	60601-1-2 Edition 4.0 2014-02	IEC
12-295	Radiology	Medical electrical equipment - Part 2-33: Particular requirements for the basic safety and essential performance of magnetic resonance equipment for medical diagnostic	60601-2-33 Ed. 3.2 B:2015	IEC
5-40	General	Medical devices - Application of risk management to medical devices	14971 Second edition 2007-03-01	ISO
5-89	General	Medical electrical equipment - Part 1-6: General requirements for basic safety and essential performance - Collateral standard: Usability	60601-1-6 Edition 3.1 2013-10	IEC
5-96	General	Medical devices – Application of usability engineering to medical devices	62366-1:2015	AAMI ANSI IEC
13-79	Software	Medical device software - Software life cycle processes	62304 Edition 1.1 2015-06	IEC
12-300	Radiology	Digital Imaging and Communications in Medicine (DICOM) Set 03/16/2012 Radiology	PS 3.1 - 3.20 (2016)	NEMA

11. Substantial Equivalence and Conclusion

The subject device, MAGNETOM Aera with *syngo* MR E11C-AP01, has the same intended use, indications for use, and fundamental technological characteristics as the predicate device, MAGNETOM Aera with *syngo* MR E11C-AP04, (K173592).

The software was modified to implement a user interface with selectable limitations for scanning patients with MR Conditional implants. Additionally the hardware was modified to implement safe communication channels and a safe cut-off path for RF power.

While there are differences in technological characteristics between the subject device and predicate device, including new and modified software applications and hardware additions, these differences have been tested and the conclusions from the non-clinical tests have shown that there were no additional questions of safety and effectiveness raised.

Siemens believes that the subject device, MAGNETOM Aera with *syngo* MR E11C-AP01 is substantially equivalent to the predicate device, MAGNETOM Aera with *syngo* MR E11C-AP04.